Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA’s Coronavirus Workload Shifting Beyond Idea Stage

Executive Summary

Pre-IND inquiries are slowing and the FDA says more late-stage development work is coming.

You may also be interested in...



COVID-19 Demands Merit A Mention In US FDA's PDUFA Fees Notice For FY 2021

The pandemic's impact was mentioned only in FDA's calculations for fees including those established by PDUFA. In addition to prescription drug applications, PDUFA fees are charged for OTC switch applications and other proposals for ingredients that are not part of an OTC monograph to be made available nonprescription.

US FDA Sets User Fees For FY2021

ANDA submission rate increases, while the NDA and BLA fee drops and the biosimilar fee is unchanged.

US FDA Sets FY 2021 User Fees, With Coronavirus (Somewhat) In Mind

ANDA submission rate increases, while the NDA and BLA fee drops and the biosimilar fee is unchanged.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel